This database contains 438 studies, archived under the term: "USA"
Click here to filter this large number of results.
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Shaw, Leslie M.,
Vanderstichele, Hugo,
Knapik-Czajka, Malgorzata,
Figurski, Michal,
Coart, Els,
Blennow, Kaj,
Soares, Holly,
Simon, Adam J.,
Lewczuk, Piotr,
Dean, Robert A.,
Siemers, Eric,
Potter, William,
Lee, Virginia M.-Y.,
Trojanowski, John Q.
The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF) concentrations of amyloid-β1-42 (Aβ(1-42)) and plaque burden measured by amyloid imaging as well as between pathologically increased levels of CSF tau and the extent of neurodegeneration measured by MRI has led to growing interest in using these biomarkers to predict the presence of AD plaque […]
Relation of hemoglobin to level of cognitive function in older persons
Shah, Raj C.,
Wilson, Robert S.,
Tang, Yuxiao,
Dong, Xinqi,
Murray, Anne,
Bennett, David A.
Background: While decreased hemoglobin concentration is common in the elderly, the relationship of the entire range of hemoglobin concentrations with cognitive function is not well understood.; Methods: Cross-sectional analyses were conducted utilizing data from community-dwelling, older persons participating in the Rush Memory and Aging Project. Proximate to first available hemoglobin measurement, 21 cognitive tests were […]
An intensive exercise program improves motor performances in patients with dementia: translational model of geriatric rehabilitation
Schwenk, Michael,
Dutzi, Ilona,
Englert, Stefan,
Micol, William,
Najafi, Bijan,
Mohler, Jane,
Hauer, Klaus
Background: Translation of intensive exercise programs developed specifically for patients with dementia into clinical settings is lacking.; Objective: To determine if a progressive resistance and functional training program, previously evaluated in dementia outpatients, can be implemented in a geriatric inpatient setting in order to improve motor performances in patients with dementia.; Methods: Eligible patients in […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Measuring the experience and perception of suffering
Schulz, R.,
Monin, J. K.,
Czaja, S. J.,
Lingler, J. H.,
Beach, S. R.,
Martire, L. M.,
Dodds, A.,
Hebert, R. S.,
Zdaniuk, B.,
Cook, T. B.
Purpose: assess psychometric properties of scales developed to assess experience and perception of physical, psychological, and existential suffering in older individuals.; Design and Methods: scales were administered to 3 populations of older persons and/or their family caregivers: individuals with Alzheimer’s disease (AD) and their family caregivers (N = 105 dyads), married couples in whom 1 […]
A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing independence at home (MIND) pilot randomized trial
Samus, Quincy M.,
Johnston, Deirdre,
Black, Betty S.,
Hess, Edward,
Lyman, Christopher,
Vavilikolanu, Amrita,
Pollutra, Jane,
Leoutsakos, Jeannie-Marie,
Gitlin, Laura N,
Rabins, Peter V.,
Lyketsos, Constantine G.
Objectives: To assess whether a dementia care coordination intervention delays time to transition from home and reduces unmet needs in elders with memory disorders.; Design: 18-month randomized controlled trial of 303 community-living elders.; Setting: 28 postal code areas of Baltimore, MD.; Participants: Age 70+ years, with a cognitive disorder, community-living, English-speaking, and having a study […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]